✎ JournalWeight & GLP-1 Medicine

Weight Loss Improves Sleep Apnea. It Does Not Reliably Cure It.

The first medication for sleep apnea is real, but it halves the problem more often than it cures it. What the AHI numbers mean, and why the CPAP stays on while the weight comes off.

Morning light filtering through sheer bedroom curtains above the edge of a bed.

A patient came in having read that a medication was approved for sleep apnea. She had been on CPAP for three years, she hated it, and she wanted to know whether she could trade the machine for a weekly injection. She had already stopped using the mask for four nights before the appointment.

The approval is real. The trade is not the one she thought she was making.

What was actually approved

On 20 December 2024 the FDA approved tirzepatide, marketed as Zepbound, for moderate to severe obstructive sleep apnea in adults with obesity, to be used alongside a reduced-calorie diet and increased physical activity. It is the first medication ever approved for this condition. Everything before it was a machine, a mouthpiece, surgery, or an implanted nerve stimulator.

The practical criteria, as the American Academy of Sleep Medicine set them out for clinicians, are a BMI of 30 or higher and an apnea-hypopnea index of 15 or more. The AHI is the number of times per hour your breathing stops or becomes shallow enough to matter. Fifteen to thirty is moderate. Above thirty is severe.

That the mechanism works is not in question, and I have written separately about why fat around the neck and upper airway collapses it during sleep, and why the resulting broken sleep then drives more weight gain. That loop is real, and this article is not about relitigating it. This article is about what happens to the machine.

What the trial showed

SURMOUNT-OSA was two parallel trials, 469 adults in total, running 52 weeks on tirzepatide at 10 or 15 mg weekly. One trial enrolled people who were unable or unwilling to use positive airway pressure. The other enrolled people already on PAP who intended to stay on it. Worth knowing before you read the numbers: the study was funded by Eli Lilly, and several authors are Lilly employees.

Mean baseline AHI was 51.5 events per hour in the first trial and 49.5 in the second. Those are not borderline numbers. Those are people whose breathing was interrupted roughly fifty times an hour, every hour, all night.

At week 52, AHI fell by 25.3 events per hour on tirzepatide against 5.3 on placebo in the first trial, a treatment difference of 20.0 with a confidence interval of 14.2 to 25.8. In the second trial it fell by 29.3 against 5.5, a difference of 23.8. Body weight fell by roughly 18% to 20% in the treated groups and by about 2% on placebo.

Those are large effects. The placebo arms barely moved, which tells you the drug is doing the work rather than the trial conditions.

The part the headline leaves out

Now do the arithmetic the press release does not do for you.

If you start at an AHI of 50 and it falls by 25, you land at 25. That is a halving. It is also still moderate obstructive sleep apnea.

The trial's key secondary endpoint was reaching an AHI below 5, or between 5 and 14 with an Epworth sleepiness score of 10 or lower. In other words, resolved, or mild and not making you sleepy. Up to 50.2% of treated participants met it.

Read that number the other way round. Roughly half did not. Half of the people on a maximally dosed GLP-1 for a full year, losing close to a fifth of their body weight, still had sleep apnea that needed treating at the end of it.

That is not a failure of the drug. It is what a severe baseline does to the arithmetic. But it is why "a medication was approved for sleep apnea" and "you can stop your CPAP" are two different sentences, and only one of them is supported. The medication is a tool rather than the whole plan, which is the same point as a GLP-1 prescription is not a treatment plan.

The arithmetic runs the other way too, and this is the group the trial did not study. If you have mild sleep apnea, say an AHI of 12, a reduction of even half that size lands you in territory that is no longer clinically significant. The people most likely to resolve their apnea through weight loss are the people who had the least of it to begin with, which is also the group the approval does not cover, since it requires an AHI of 15 or higher. If that is you, the conversation with your physician is about weight and metabolic health on their own merits, and the airway is a reason to have it sooner.

The AASM's own position is explicit: this is not a replacement for PAP therapy. Their clinician guidance says many patients will still need PAP or another treatment, and that PAP requirements should be reassessed as AHI improves rather than abandoned on the assumption that it has.

Not every sleep apnea is a weight problem

The approval is for obesity-related obstructive sleep apnea, and the qualifier matters. It is also specific to one drug, because tirzepatide and semaglutide are not the same drug, and only tirzepatide carries this indication.

Airway collapse has several contributors and body weight is only one. Jaw position, tongue size, tonsils, nasal obstruction and the inherited shape of the upper airway all determine how easily it closes. Plenty of people with a normal BMI have significant obstructive sleep apnea, and losing weight they do not have to lose will not fix an anatomically narrow airway.

Weight contributes in two distinct ways, and they are often collapsed into one. Fat deposited around the neck and in the tongue narrows the airway directly. Fat in the abdomen and chest wall reduces lung volume, and lower lung volume makes the airway above it less stable. The second mechanism is the one patients have never heard of, and it is part of why waist measurement predicts apnea severity even when neck circumference does not.

Central sleep apnea, where the problem is the brain's respiratory drive rather than a blocked airway, is a different condition and is not what was approved here.

So the honest version of the question is not "will losing weight cure my sleep apnea." It is "how much of my sleep apnea is weight, and how much is architecture." Those proportions differ by person, and nobody can tell you yours from the outside.

What I actually do

If a patient with obesity and moderate to severe OSA is a reasonable candidate, I will treat both at once, and the sequence matters.

The machine stays on while the weight comes off. There is no interval during which it is sensible to be untreated. A year of untreated severe apnea is a year of nocturnal hypoxia, elevated sympathetic tone, worse blood pressure and worse insulin resistance, and all of it works against the weight loss you are attempting.

Reassess with a test, not a feeling. Once weight has stabilised at its lowest point, repeat sleep testing, whether a home study or a full polysomnogram, tells you where the AHI actually landed. Feeling better is not a measurement. People feel better on effective CPAP too, which is the point of it.

Then adjust. If the repeat study shows the AHI has dropped into a range where pressure can be lowered or therapy stepped down, that is a decision made on data. Some patients do come off PAP. That outcome is earned by a number, not assumed from a prescription. The same discipline applies to the medication itself, which is the subject of what to check before raising the dose.

Know the contraindications before you ask for it. A personal or family history of medullary thyroid carcinoma or MEN 2 rules it out, as does pregnancy. Significant gastroparesis or other gastrointestinal motility disease, a history of pancreatitis, and gallbladder disease all need weighing first. In the trial, serious adverse events occurred in 7.5% of participants overall, and there were two adjudicated cases of acute pancreatitis.

The question nobody asks until later

What happens if you stop the medication.

Weight regain after discontinuation is well established and the AASM says so plainly. What is less well documented is what the AHI does afterwards, because the trials did not follow people off treatment to find out. The reasonable expectation is that apnea severity tracks weight back upward, since that is the mechanism by which it improved. I would call that likely rather than demonstrated, and I would want anyone starting this to think of it as an ongoing treatment rather than a course. That is also why there are four things to learn while the medication is still working, before any conversation about stopping it.

My patient restarted her CPAP that evening. She also started tirzepatide, and we will retest her in about a year when her weight has settled. She may well end up needing less pressure. She may end up off the machine. What she will not do is find out by guessing, four nights at a time, while her airway closes fifty times an hour.

Sources: FDA, approval of the first medication for obstructive sleep apnea · AASM, statement on the Zepbound approval · SURMOUNT-OSA, New England Journal of Medicine (2024)

If any of this sounds like your experience, you can book a virtual consultation with Dr. Sater to review your history and testing in full.

This article is educational and is not individual medical advice. Speak with a qualified physician about your own health before making changes to your care.

Personalized care

Your health story deserves to be heard.

Explore a root-cause approach built around you—not just your lab results.

Book a consultation →